Hollister and Heavy Grass Collaborate with Slipknot Co-Founder Shawn "Clown" Crahan on New HashBone Line

Crahan is a multi-platinum, Grammy-winning artist who has sold more than 30 million albums. Clown's signature HashBone pre-roll packs will mark the first co-branded release from the Hollister-Heavy Grass licensing agreement. The products will initially be launched on May 17th in select dispensaries in California and on DreamyDelivery.com .

Hollister Biosciences Inc. (CSE: HOLL) (OTC: HSTRF) (FRANKFURT: HOB) (the " Company ", " Hollister Cannabis Co. " or " Hollister ") and Heavy Grass have partnered with Slipknot co-founder Shawn "Clown" Crahan for special-edition HashBone packs featuring six half-gram pre-rolls and matches in a soft-touch matte black case. The multi-platinum, Grammy-winning artist has sold more than 30 million records with Slipknot, whose last three albums debuted at No. 1 on both the Billboard 200 and the U.K. Albums Chart.

Hollister Biosciences Inc. (CNW Group/Hollister Biosciences Inc.)

Branded with original artwork, Clown's signature HashBone line contains a potent uplifting blend of 75% indica flower and 25% Paradise Citrus bubble hash. The signature premium indica flower features an earthy citrus-rich flavor profile with sublime sedating effects. Paradise Citrus, made from crossing Tropicana Cookies and Tina, adds another layer of full-body relaxation with happy head highs and citrusy notes of orchard-fresh sour orange. Lab testing confirms the potency of these hash-infused pre-rolls with THC levels above 40%.

Shawn "Clown" Crahan is a multi-talented artist who co-founded Slipknot, directed most of its music videos and serves as one of the primary songwriters. Clown is also the creative force behind Slipknot's iconic visuals, originating the masks and uniforms, creating album covers, packaging, live staging and visuals, and all merchandise.

Heavy Grass is a California cannabis brand with deep roots in the hard rock and heavy metal music community. In 2020 (see press release dated July 28, 2020 ), Hollister entered into a licensing agreement with Heavy Grass to produce and sell co-branded cannabis products primarily through collaborations with its music partners. HashBone, a leading hash-infused pre-roll in California , is one of Hollister's signature products, and the Clown HashBone line represents the first collaborative release between Hollister , Heavy Grass and one of its artists.

"We are very excited to be launching our HashBone collaboration with Clown. We couldn't ask for a better partner and someone who is true to the plant. This partnership is our first step in combining hard rock/metal with cannabis in a truly authentic way," says Carl Saling , the Co-Founder, CEO and Director of Hollister Biosciences. "Additionally, we are happy that we get to bring Clown to market in tandem with our friends at Heavy Grass - leveraging their experience in music-inspired cannabis products will amplify our overall marketing efforts."

Clown, a long-time cannabis connoisseur, is also an advocate for its potential therapeutic benefits. He adds, "Just remember, it's medicine."

In celebration of the release of Clown Cannabis, Clown and Heavy Grass are offering a once in a lifetime Green Ticket experience. The winner of Clown's Green Ticket will receive unlimited entrance for two into any Slipknot shows in the world for the next three years. For entry details visit theheavygrass.com .

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state company with a portfolio of innovative, high-quality cannabis & hemp branded consumer products and white-labeling manufacturing. Our products are sold in 370 dispensaries across Arizona and California . Hollister Biosciences wholly-owned brand, Venom Extracts, is a category-leading brand that sold more than 4 million grams in 2020, accounting for up to 30 percent of category sales in Arizona .

Products from Hollister Biosciences Inc. include HashBone, the brand's premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products and full-spectrum high CBD pet tinctures. Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA , birthplace of the "American Biker".

Website:   www.hollisterbiosciences.co , www.hollistercannabisco.com
  Instagram: @hashbones @hollistercannabisco

About Heavy Grass
Heavy Grass is a California cannabis brand that honors the legacy and lifestyle of heavy music by plugging in, getting loud and blazing up. We work with top California cultivators to provide both high quality and high potency products to our fans at an affordable price.  We want fans to spend money on a good time, not overpriced weed. www.theheavygrass.com | @heavygrassofficial

The CSE, nor its regulation services provider, does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain statements that may be deemed "forward-looking statements". The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "would", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/hollister-and-heavy-grass-collaborate-with-slipknot-co-founder-shawn-clown-crahan-on-new-hashbone-line-301292616.html

SOURCE Hollister Biosciences Inc.

Cision View original content to download multimedia: https://www.newswire.ca/en/releases/archive/May2021/17/c2088.html

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)

Compass Pathways to participate in Stifel 2024 Healthcare Conference

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the Stifel 2024 Healthcare Conference at 10:55 am ET on November 19, 2024.

A live audio webcast of the presentation will be accessible from the "Events" page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Compass Pathways Announces Third Quarter 2024 Financial Results and Business Updates

  • Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression now expected in second quarter 2025
  • COMP006 data will now be announced after 26-week time point, expected in the second half of 2026
  • Strategic reorganization to focus all efforts on COMP360 program resulting in reduction of workforce of approximately 30%
  • Cash position of $207 million
  • Conference call October 31 at 8:00 am ET (12:00 pm UK)

Compass Pathways plc (Nasdaq: CMPS) ("Compass"), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2024 and an update on recent business progress.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Emyria Limited

Emyria and UWA in Partnership to Commercialise Novel Serotonin-Releasing Agents for Mental Health and Neurology

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) has signed an exclusive licence agreement with UWA, granting worldwide rights to a rapidly growing portfolio of selective serotonin-releasing agents. (See Appendix for Key Commercial Terms). These novel compounds, realised through a UWA–Emyria research partnership launched in 2021,2 include potential next-generation treatments for mental health and neurological conditions such as PTSD and Parkinson’s disease.

Keep reading...Show less

Seelos Announces Second Postponement of its Annual Meeting of Stockholders

Seelos Therapeutics, Inc. (OTCQB: SEEL) ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that its 2024 Annual Meeting of Stockholders (the "Annual Meeting"), which was previously postponed to Friday, October 25, 2024 from its originally scheduled date of Friday, September 27, 2024 has been further postponed. The Annual Meeting is now scheduled to be held virtually, via live webcast at www.virtualshareholdermeeting.comSEEL2024 on Monday, November 25, 2024 at 8:00 a.m., Eastern Time . The record date for the Annual Meeting, August 19, 2024 is unchanged and applies to the postponed Annual Meeting.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Compass Pathways to Announce Third Quarter Financial Results on October 31, 2024

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter 2024 ending September 30, 2024, and provide an update on recent business developments, on October 31, 2024.

The management team will host a conference call at 8:00 am ET (12:00 pm UK) on October 31, 2024. To access the call, please register in advance here to obtain a local or toll-free phone number and your personal pin.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Quantum Biopharm (CSE: QNTM)

Quantum BioPharma Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing

Christian Attar Law Firm and Freedman Normand Friedland LLP, in conjunction with forensic investigators, have uncovered evidence of a potential multi-year market manipulation scheme that has caused substantial damages to the Company and its shareholders


Keep reading...Show less

Latest Press Releases

Related News

×